We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+15.06%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$146M
AUM Growth
+$16.5M
Cap. Flow
+$7.36M
Cap. Flow %
5.05%
Top 10 Hldgs %
90.62%
Holding
26
New
3
Increased
4
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$20.3M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$8.7M
3
AERI
Aerie Pharmaceuticals
AERI
+$6.28M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$3.9M
5
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$2.72M

Top Sells

Rank Stock Value
1
WVE icon
Wave Life Sciences
WVE
+$6.88M
2
RGLS
Regulus Therapeutics
RGLS
+$5.47M
3
LRMR icon
Larimar Therapeutics
LRMR
+$3.38M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$3.3M
5
XENT
Intersect ENT, Inc
XENT
+$3.2M

Sector Composition

Rank Sector Weight
1 Healthcare 82.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDR
1
DELISTED
Alder Biopharmaceuticals
ALDR
$40M 27.42%
1,600,183
+321,613
+25% +$8.7M
AERI
2
DELISTED
Aerie Pharmaceuticals
AERI
$23.7M 16.25%
1,345,313
+388,187
+41% +$6.28M
WVE icon
3
Wave Life Sciences
WVE
$1.12B
$20.1M 13.77%
970,104
-441,645
-31% -$6.88M
NTLA icon
4
Intellia Therapeutics
NTLA
$1.46B
$16.3M 11.19%
+763,688
New +$20.3M
GBT
5
DELISTED
Global Blood Therapeutics, Inc.
GBT
$11.5M 7.86%
690,269
+193,269
+39% +$3.9M
ARDX icon
6
Ardelyx
ARDX
$1.25B
$5.25M 3.6%
601,485
-46,855
-7% -$383K
EPZM
7
DELISTED
Epizyme, Inc
EPZM
$5.24M 3.6%
511,777
+35,000
+7% +$390K
AVXS
8
DELISTED
AveXis, Inc. Common Stock
AVXS
$3.62M 2.48%
95,173
-73,022
-43% -$2.47M
NDRM
9
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$3.27M 2.25%
201,469
-90,902
-31% -$1.53M
LRMR icon
10
Larimar Therapeutics
LRMR
$392M
$3.22M 2.21%
44,791
-42,779
-49% -$3.38M
SYRS
11
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.72M 1.87%
+15,000
New +$2.72M
BLCM
12
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$2.67M 1.83%
20,599
– –
AKTX
13
Akari Therapeutics
AKTX
$14.4M
$2.66M 1.82%
246
-84
-25% -$1.08M
AIMT
14
DELISTED
Aimmune Therapeutics
AIMT
$2.54M 1.74%
235,020
-120,000
-34% -$1.63M
OREX
15
DELISTED
Orexigen Therapeutics, Inc.
OREX
$1.09M 0.75%
254,258
-48,477
-16% -$219K
LPCN icon
16
Lipocine
LPCN
$17.8M
$920K 0.63%
17,802
-5,557
-24% -$861K
NSTG
17
DELISTED
NanoString Technologies, Inc.
NSTG
$895K 0.61%
+71,000
New +$1.03M
BDSI
18
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$166K 0.11%
70,177
-137,321
-66% -$379K
EDIT icon
19
Editas Medicine
EDIT
$394M
– –
-14,500
Closed -$501K
RGNX icon
20
Regenxbio
RGNX
$599M
– –
-100,000
Closed -$1.08M
RGLS
21
DELISTED
Regulus Therapeutics
RGLS
– –
-6,576
Closed -$5.47M
SGMO
22
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-544,816
Closed -$3.3M
IMGN
23
DELISTED
Immunogen Inc
IMGN
– –
-42,815
Closed -$365K
XENT
24
DELISTED
Intersect ENT, Inc
XENT
– –
-168,550
Closed -$3.2M
XLRN
25
DELISTED
Acceleron Pharma
XLRN
– –
-94,403
Closed -$2.49M
1
2

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q2 2016 Portfolio in Review

As of Q2 2016, Foresite Capital Management III held 26 positions worth $146M, up 13% from $129M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Foresite Capital Management III deployed $7.36M of net new capital in Q2 2016, opening 3 new positions and adding to 4 existing holdings. Its largest new stake was Intellia Therapeutics: 763,688 shares worth $16.3M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 85% a quarter earlier.

On the sell side, the largest reduction was Wave Life Sciences, an estimated $6.88M trimmed.

  • Foresite Capital Management III's largest Q2 2016 buy was Intellia Therapeutics: 763,688 shares worth $16.3M.
  • Foresite Capital Management III added most to Alder Biopharmaceuticals in Q2 2016, an estimated $8.7M increase.
  • Foresite Capital Management III's biggest Q2 2016 reduction was Wave Life Sciences, cutting an estimated $6.88M.
  • Foresite Capital Management III fully exited Regulus Therapeutics in Q2 2016, selling an estimated $5.47M.
  • Foresite Capital Management III's ten largest holdings make up 91% of its $146M portfolio in Q2 2016.
  • Foresite Capital Management III opened 3 new positions and closed 8 in Q2 2016.
  • Foresite Capital Management III's portfolio value rose 13% quarter-over-quarter to $146M.

Based on Foresite Capital Management III's 13F filing for Q2 2016, filed 12 Aug 2016.